The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study

A Zaphiriou, S Robb, T Murray‐Thomas… - European journal of …, 2005 - Wiley Online Library
Objectives To determine the diagnostic accuracy of the measurement of plasma B‐type
natriuretic peptide (BNP) and N‐terminal pro‐BNP (NTproBNP) in patients referred by their …

Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non–ST-segment elevation myocardial infarction …

JC Tardif, JF Tanguay, SR Wright, V Duchatelle… - Journal of the American …, 2013 - jacc.org
Objectives: The study aimed to evaluate inclacumab for the reduction of myocardial damage
during a percutaneous coronary intervention (PCI) in patients with non–ST-segment …

The index of microcirculatory resistance measured acutely predicts the extent and severity of myocardial infarction in patients with ST-segment elevation myocardial …

R McGeoch, S Watkins, C Berry, T Steedman… - JACC: Cardiovascular …, 2010 - jacc.org
Objectives: This study investigated the relationship between the index of microcirculatory
resistance (IMR) with myocardial injury and microvascular obstruction (MVO) assessed by …

Retrospective analysis of thecost-effectiveness of using plasmabrain natriuretic peptide inscreening for left ventricularsystolic dysfunction in the general population

OW Nielsen, TA McDonagh, SD Robb… - Journal of the American …, 2003 - jacc.org
Objectives: We sought to assess the cost-effectiveness of using plasma brain natriuretic
peptide (BNP) as a pre-echocardiographic screening test for left ventricular systolic …

Effects of the P‐selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention according to timing of infusion: insights from the …

BE Stähli, C Gebhard, V Duchatelle… - Journal of the …, 2016 - Am Heart Assoc
Background The Effects of the P‐Selectin Antagonist Inclacumab on Myocardial Damage
After Percutaneous Coronary Intervention for Non‐ST‐Segment Elevation Myocardial …

Efficacy and safety of bevacizumab-containing therapy in newly diagnosed ovarian cancer: ROSiA single-arm phase 3B study

AM Oza, F Selle, I Davidenko, J Korach… - International Journal of …, 2017 - ijgc.bmj.com
Objective The aim of this study was to assess the safety and efficacy of extending
bevacizumab therapy beyond 15 months in nonprogressive ovarian cancer. Patients and …

[HTML][HTML] Real-world treatment patterns and clinical outcomes in patients with stage III NSCLC: results of KINDLE, a multicountry observational study

AR Jazieh, HC Onal, DSW Tan, RA Soo… - Journal of Thoracic …, 2021 - Elsevier
Abstract Introduction Stage III NSCLC is a heterogeneous disease requiring a multimodal
management approach. We conducted a real-world, global study to characterize patients …

Brain natriuretic peptide is stable in whole blood and can be measured using a simple rapid assay: implications for clinical practice

DR Murdoch, J Byrne, JJ Morton, TA McDonagh… - Heart, 1997 - heart.bmj.com
Objectives To compare the stability of brain natriuretic peptide (BNP) to that of N-terminal
atrial natriuretic peptide (NT-ANP) in whole blood and plasma stored under different …

[HTML][HTML] Effects of P-selectin antagonist inclacumab in patients undergoing coronary artery bypass graft surgery: SELECT-CABG trial

BE Stähli, JC Tardif, M Carrier, R Gallo… - Journal of the American …, 2016 - jacc.org
Please note: This work was supported by a grant from the Société Française de Cardiologie.
Dr. Clementy has received funding for conference travel and educational symposia from …

Cancer cell detection device for the diagnosis of bladder cancer from urine

M MacGregor, HS Shirazi, KM Chan, K Ostrikov… - Biosensors and …, 2021 - Elsevier
Bladder cancer is common and has one of the highest recurrence rates. Cystoscopy, the
current gold standard diagnosis approach, has recently benefited from the introduction of …